Review



anti-human cd11b antibody brilliant ultra violet 496  (Thermo Fisher)


Bioz Verified Symbol Thermo Fisher is a verified supplier
Bioz Manufacturer Symbol Thermo Fisher manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Thermo Fisher anti-human cd11b antibody brilliant ultra violet 496
    MTL-CEBPA sensitizes MOLM-14 cells to the anti-proliferative effects of FLT3 inhibitors (A) Heatmap of FLT3 inhibitors showing IC 50 values when combined with MTL-CEBPA or control (MTL-FLUC) in MOLM-14-Ven-Luc cells. The fold change in the IC50 (control vs. MLT-CEBPA) for each FLT3 inhibitor is listed next to the heatmap. (B) Difference in gilteritinib IC 50 in MOLM-14-Ven-Luc cells treated with MTL-CEBPA or control (MTL-FLUC). Two-way unpaired student t test; n = 3. Data represented as mean (SD). (C) Growth curves for MOLM-14 cells following treatment with 10 μg/mL of MTL-CEBPA or control (MTL-FLUC) with and without 5 nM gilteritinib. Two-way ANOVA with Holm-Sidak multiple comparison test; n = 6. Data represented as mean (SEM). (D) Percent viability of cells on day 6. Two-way unpaired student t test; n = 6. Data represented as mean (SD). (E) Decrease in c-Myc expression overtime after treatment with 10 μg/mL MTL-CEBPA. One-way ANOVA with Holm-Sidak multiple comparison test; n = 2–3. Data represented as mean (SD). (F) Representative western blot of c-Myc expression over time in MOLM-14 cells. (G) Fold change in <t>CD11b</t> MFI and (H) CD14 MFI in MOLM-14 cells 96 h following treatment with 10 μg/mL MTL-CEBPA or control (untreated). Two-way unpaired student t test; n = 2–3. Data represented as mean (SD).
    Anti Human Cd11b Antibody Brilliant Ultra Violet 496, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti-human cd11b antibody brilliant ultra violet 496/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    anti-human cd11b antibody brilliant ultra violet 496 - by Bioz Stars, 2026-01
    90/100 stars

    Images

    1) Product Images from "RNA activation of CEBPA improves leukemia treatment"

    Article Title: RNA activation of CEBPA improves leukemia treatment

    Journal: Molecular Therapy. Nucleic Acids

    doi: 10.1016/j.omtn.2025.102611

    MTL-CEBPA sensitizes MOLM-14 cells to the anti-proliferative effects of FLT3 inhibitors (A) Heatmap of FLT3 inhibitors showing IC 50 values when combined with MTL-CEBPA or control (MTL-FLUC) in MOLM-14-Ven-Luc cells. The fold change in the IC50 (control vs. MLT-CEBPA) for each FLT3 inhibitor is listed next to the heatmap. (B) Difference in gilteritinib IC 50 in MOLM-14-Ven-Luc cells treated with MTL-CEBPA or control (MTL-FLUC). Two-way unpaired student t test; n = 3. Data represented as mean (SD). (C) Growth curves for MOLM-14 cells following treatment with 10 μg/mL of MTL-CEBPA or control (MTL-FLUC) with and without 5 nM gilteritinib. Two-way ANOVA with Holm-Sidak multiple comparison test; n = 6. Data represented as mean (SEM). (D) Percent viability of cells on day 6. Two-way unpaired student t test; n = 6. Data represented as mean (SD). (E) Decrease in c-Myc expression overtime after treatment with 10 μg/mL MTL-CEBPA. One-way ANOVA with Holm-Sidak multiple comparison test; n = 2–3. Data represented as mean (SD). (F) Representative western blot of c-Myc expression over time in MOLM-14 cells. (G) Fold change in CD11b MFI and (H) CD14 MFI in MOLM-14 cells 96 h following treatment with 10 μg/mL MTL-CEBPA or control (untreated). Two-way unpaired student t test; n = 2–3. Data represented as mean (SD).
    Figure Legend Snippet: MTL-CEBPA sensitizes MOLM-14 cells to the anti-proliferative effects of FLT3 inhibitors (A) Heatmap of FLT3 inhibitors showing IC 50 values when combined with MTL-CEBPA or control (MTL-FLUC) in MOLM-14-Ven-Luc cells. The fold change in the IC50 (control vs. MLT-CEBPA) for each FLT3 inhibitor is listed next to the heatmap. (B) Difference in gilteritinib IC 50 in MOLM-14-Ven-Luc cells treated with MTL-CEBPA or control (MTL-FLUC). Two-way unpaired student t test; n = 3. Data represented as mean (SD). (C) Growth curves for MOLM-14 cells following treatment with 10 μg/mL of MTL-CEBPA or control (MTL-FLUC) with and without 5 nM gilteritinib. Two-way ANOVA with Holm-Sidak multiple comparison test; n = 6. Data represented as mean (SEM). (D) Percent viability of cells on day 6. Two-way unpaired student t test; n = 6. Data represented as mean (SD). (E) Decrease in c-Myc expression overtime after treatment with 10 μg/mL MTL-CEBPA. One-way ANOVA with Holm-Sidak multiple comparison test; n = 2–3. Data represented as mean (SD). (F) Representative western blot of c-Myc expression over time in MOLM-14 cells. (G) Fold change in CD11b MFI and (H) CD14 MFI in MOLM-14 cells 96 h following treatment with 10 μg/mL MTL-CEBPA or control (untreated). Two-way unpaired student t test; n = 2–3. Data represented as mean (SD).

    Techniques Used: Control, Comparison, Expressing, Western Blot



    Similar Products

    anti-human cd11b antibody brilliant ultra violet 496  (Thermo Fisher)
    90
    Thermo Fisher anti-human cd11b antibody brilliant ultra violet 496
    MTL-CEBPA sensitizes MOLM-14 cells to the anti-proliferative effects of FLT3 inhibitors (A) Heatmap of FLT3 inhibitors showing IC 50 values when combined with MTL-CEBPA or control (MTL-FLUC) in MOLM-14-Ven-Luc cells. The fold change in the IC50 (control vs. MLT-CEBPA) for each FLT3 inhibitor is listed next to the heatmap. (B) Difference in gilteritinib IC 50 in MOLM-14-Ven-Luc cells treated with MTL-CEBPA or control (MTL-FLUC). Two-way unpaired student t test; n = 3. Data represented as mean (SD). (C) Growth curves for MOLM-14 cells following treatment with 10 μg/mL of MTL-CEBPA or control (MTL-FLUC) with and without 5 nM gilteritinib. Two-way ANOVA with Holm-Sidak multiple comparison test; n = 6. Data represented as mean (SEM). (D) Percent viability of cells on day 6. Two-way unpaired student t test; n = 6. Data represented as mean (SD). (E) Decrease in c-Myc expression overtime after treatment with 10 μg/mL MTL-CEBPA. One-way ANOVA with Holm-Sidak multiple comparison test; n = 2–3. Data represented as mean (SD). (F) Representative western blot of c-Myc expression over time in MOLM-14 cells. (G) Fold change in <t>CD11b</t> MFI and (H) CD14 MFI in MOLM-14 cells 96 h following treatment with 10 μg/mL MTL-CEBPA or control (untreated). Two-way unpaired student t test; n = 2–3. Data represented as mean (SD).
    Anti Human Cd11b Antibody Brilliant Ultra Violet 496, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti-human cd11b antibody brilliant ultra violet 496/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    anti-human cd11b antibody brilliant ultra violet 496 - by Bioz Stars, 2026-01
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    MTL-CEBPA sensitizes MOLM-14 cells to the anti-proliferative effects of FLT3 inhibitors (A) Heatmap of FLT3 inhibitors showing IC 50 values when combined with MTL-CEBPA or control (MTL-FLUC) in MOLM-14-Ven-Luc cells. The fold change in the IC50 (control vs. MLT-CEBPA) for each FLT3 inhibitor is listed next to the heatmap. (B) Difference in gilteritinib IC 50 in MOLM-14-Ven-Luc cells treated with MTL-CEBPA or control (MTL-FLUC). Two-way unpaired student t test; n = 3. Data represented as mean (SD). (C) Growth curves for MOLM-14 cells following treatment with 10 μg/mL of MTL-CEBPA or control (MTL-FLUC) with and without 5 nM gilteritinib. Two-way ANOVA with Holm-Sidak multiple comparison test; n = 6. Data represented as mean (SEM). (D) Percent viability of cells on day 6. Two-way unpaired student t test; n = 6. Data represented as mean (SD). (E) Decrease in c-Myc expression overtime after treatment with 10 μg/mL MTL-CEBPA. One-way ANOVA with Holm-Sidak multiple comparison test; n = 2–3. Data represented as mean (SD). (F) Representative western blot of c-Myc expression over time in MOLM-14 cells. (G) Fold change in CD11b MFI and (H) CD14 MFI in MOLM-14 cells 96 h following treatment with 10 μg/mL MTL-CEBPA or control (untreated). Two-way unpaired student t test; n = 2–3. Data represented as mean (SD).

    Journal: Molecular Therapy. Nucleic Acids

    Article Title: RNA activation of CEBPA improves leukemia treatment

    doi: 10.1016/j.omtn.2025.102611

    Figure Lengend Snippet: MTL-CEBPA sensitizes MOLM-14 cells to the anti-proliferative effects of FLT3 inhibitors (A) Heatmap of FLT3 inhibitors showing IC 50 values when combined with MTL-CEBPA or control (MTL-FLUC) in MOLM-14-Ven-Luc cells. The fold change in the IC50 (control vs. MLT-CEBPA) for each FLT3 inhibitor is listed next to the heatmap. (B) Difference in gilteritinib IC 50 in MOLM-14-Ven-Luc cells treated with MTL-CEBPA or control (MTL-FLUC). Two-way unpaired student t test; n = 3. Data represented as mean (SD). (C) Growth curves for MOLM-14 cells following treatment with 10 μg/mL of MTL-CEBPA or control (MTL-FLUC) with and without 5 nM gilteritinib. Two-way ANOVA with Holm-Sidak multiple comparison test; n = 6. Data represented as mean (SEM). (D) Percent viability of cells on day 6. Two-way unpaired student t test; n = 6. Data represented as mean (SD). (E) Decrease in c-Myc expression overtime after treatment with 10 μg/mL MTL-CEBPA. One-way ANOVA with Holm-Sidak multiple comparison test; n = 2–3. Data represented as mean (SD). (F) Representative western blot of c-Myc expression over time in MOLM-14 cells. (G) Fold change in CD11b MFI and (H) CD14 MFI in MOLM-14 cells 96 h following treatment with 10 μg/mL MTL-CEBPA or control (untreated). Two-way unpaired student t test; n = 2–3. Data represented as mean (SD).

    Article Snippet: Anti-human CD11b antibody (Brilliant Ultra Violet 496, mouse, monoclonal, 1:1000, eBioscience, clone ICRF44) or anti-human CD14 antibody (Brilliant Violet 421, mouse, monoclonal, BioLegend, clone HCD14) was diluted in 2% FBS/PBS to the manufacturer-recommended concentration, and cells were incubated on ice in the dark with 100 μL of the solution for 30 min.

    Techniques: Control, Comparison, Expressing, Western Blot